LDS/Medical Tests/HLA-B*5801 Genotype, Allopurinol Hypersensitivity

HLA-B*5801 Genotype, Allopurinol Hypersensitivity

HLA-B*58:01 allele is located in the class I HLA region of the short arm (p) of chromosome 6 at positions 21.1-21.3. This allele is one among more than 1500 members of the HLA-B allele family which are responsible for the presentation of peptides to immune cells, specifically to T-lymphocytes, and elicit immune responses in the body. This allele is clinically significant for its relationship to severe or fatal sensitivity reactions with the drug allopurinol.

Allopurinol is the drug of choice in treating patients with hyperuricemic conditions such as gout. This drug acts by inhibiting the enzyme xanthine oxidase of the purine degradation pathway blocking the conversion of xanthine to uric acid. Allopurinol and its metabolite oxypurinol are known to directly interact with the HLA B5801 resulting in the activation of self-reactive T-lymphocytes. Patients with a history of alcohol abuse, cigarette smoking, chronic kidney diseases (through increased oxypurinol saturation in plasma), and patients receiving allopurinol dosage exceeding 300 mg/day are more vulnerable to hypersensitivity reactions.

Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are the most common manifestations of allopurinol hypersensitivity that manifests around 6 to 8 weeks after administration. The skin reaction is typically preceded by several days of fever, conjunctival itching or burning, and pain on swallowing. Skin lesions are typically ill-defined coalescing erythematous macules with purpuric centers. Lesions typically start on the face and thorax and spread symmetrically. Lesions may occur around the mouth, nose, and genitals and may progress with crusting and erosions. Anemia and lymphopenia are commonly seen. Eosinophilia is uncommon but neutropenia may occur in one third of patients and correlates with a poor prognosis. The incidence of SJS/TEN has been increasing with approximately 6 cases per 1000 patients treated with allopurinol. Mortality can exceed 25%.

Current guidelines from the Clinical Pharmacogenomics Implementation Consortium (CPIC) and the 2020 American College of Rheumatology Guideline for the Management of Gout recommend HLA-B*58:01 genotyping before prescribing allopurinol. Patients who test positive for the allele should not take allopurinol due to the increased risk of severe cutaneous adverse reactions (SCAR).

  • As an aid in identifying individuals susceptible to allopurinol hypersensitivity syndrome prior to administration
  • Pharmacogenetics for therapy selection and management of gout in Asian and African patients
Positivity for HLA B*50:01 allele indicates susceptibility to allopurinol hypersensitivity. An alternative drug regimen should be followed. Negative test for HLA B*50:01 allele indicates insusceptibility to allopurinol hypersensitivity, but alternatives should be used if symptoms show up.

Negative for HLA B*50:01 allele

Allele specific primer extension by Real Time- PCR (ARMS), Sequence-Specific Oligonucleotide Probe (SSOP) hybridization, Sequence-Based Typing (SBT).

Whole Blood, Buccal swabs. Container: Lavender (EDTA) or Yellow (ACD vial), Buccal swab kit.

Stability Whole blood

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: unstable
Skin biopsy, urea, creatinine, uric acid, rheumatoid factor, ANA, Anti-CCP, Liver function tests, plasma allopurinol concentration, complete blood count, ESR and C-reactive protein.
3 – 7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login